Syndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on Wednesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 8th. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.96) per share for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ SNDX traded down $0.29 during mid-day trading on Thursday, hitting $21.68. The company had a trading volume of 8,284 shares, compared to its average volume of 1,119,265. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -7.45 and a beta of 1.01. Syndax Pharmaceuticals has a 1 year low of $11.22 and a 1 year high of $25.34. The stock’s 50-day moving average price is $22.60 and its 200-day moving average price is $19.80.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SNDX shares. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Scotiabank lowered Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their price objective for the company from $36.00 to $23.00 in a research note on Wednesday, January 31st. HC Wainwright reissued a “buy” rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research note on Friday, April 26th. Finally, JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.42.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).